Molecular Imaging in Cancer Drug Development.

Area of Science:

• Oncology
• Radiochemistry
• Pharmacology

Background:

• Oncology drug development faces high attrition rates despite advances in understanding cancer biology.
• The oncology field leads therapeutic research but requires efficient methods to select promising drug candidates.
• Molecular imaging is emerging as a key tool for early-stage decision-making in oncology drug development.

Purpose of the Study:

• To review the current applications of molecular imaging in the development of anticancer drugs.
• To highlight the role of molecular imaging in supporting go/no-go decisions during drug development.
• To discuss the use of Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) in preclinical and clinical oncology research.

Main Methods:

• Radiolabeling of drug candidates with suitable radionuclides.
• In vivo visualization of drug distribution, target engagement, and pharmacokinetics using PET and SPECT.
• Analysis of whole-body drug distribution and target expression heterogeneity.

Main Results:

• Molecular imaging provides critical in vivo data on drug behavior and target interactions.
• Techniques like PET and SPECT enable visualization of drug distribution and target expression.
• Imaging aids in assessing drug efficacy and identifying patient populations likely to respond.

Conclusions:

• Molecular imaging is instrumental in optimizing oncology drug development pipelines.
• It offers valuable insights into drug pharmacokinetics, pharmacodynamics, and target engagement.
• The application of molecular imaging enhances the efficiency and success rate of novel anticancer drug development.